D. Boral Capital Reaffirms "Buy" Rating for Pulmonx (NASDAQ:LUNG)

Key Points

• D. Boral Capital has reaffirmed a "Buy" rating for Pulmonx, maintaining a price target of $16.00 despite varying opinions from other analysts.
• Multiple analysts have recently lowered their price targets for Pulmonx, with estimates ranging significantly, indicating uncertainty in the stock's prospects.
• Pulmonx reported a quarterly EPS of ($0.38), which surpassed expectations, alongside a revenue of $23.86 million, indicating potential resilience in performance.

Pulmonx (NASDAQ:LUNG - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $16.00 price target on the stock.

Several other equities analysts have also recently commented on the stock. Stifel Nicolaus dropped their target price on shares of Pulmonx from $16.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday, July 31st. Wells Fargo & Company decreased their price target on shares of Pulmonx from $6.00 to $3.00 and set an "equal weight" rating on the stock in a report on Friday, August 1st. Piper Sandler lowered shares of Pulmonx from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $9.00 to $2.50 in a report on Thursday, July 31st. Citigroup decreased their price target on shares of Pulmonx from $6.50 to $4.15 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Finally, Wall Street Zen raised shares of Pulmonx from a "sell" rating to a "hold" rating in a report on Saturday, August 30th. Five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $7.66.

Pulmonx Price Performance

Shares of NASDAQ:LUNG opened at $1.74 on Monday. The firm has a 50 day moving average of $2.25 and a 200-day moving average of $4.10. The stock has a market capitalization of $70.91 million, a PE ratio of -1.22 and a beta of 0.43. The company has a current ratio of 5.35, a quick ratio of 4.63 and a debt-to-equity ratio of 0.54. Pulmonx has a 12 month low of $1.47 and a 12 month high of $9.37.

Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.02. The company had revenue of $23.86 million during the quarter, compared to analysts' expectations of $23.46 million. Pulmonx had a negative net margin of 62.88% and a negative return on equity of 69.76%. Pulmonx has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Pulmonx will post -1.55 EPS for the current fiscal year.

Insider Activity

In other news, Director Richard Ferrari sold 8,000 shares of the business's stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $3.16, for a total value of $25,280.00. Following the transaction, the director owned 87,024 shares in the company, valued at approximately $274,995.84. The trade was a 8.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 41,896 shares of company stock valued at $79,514. 6.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE lifted its position in shares of Pulmonx by 556.6% in the 2nd quarter. Bank of America Corp DE now owns 481,268 shares of the company's stock worth $1,246,000 after purchasing an additional 407,971 shares during the period. Jane Street Group LLC lifted its position in shares of Pulmonx by 3,328.7% in the 2nd quarter. Jane Street Group LLC now owns 88,631 shares of the company's stock worth $230,000 after purchasing an additional 86,046 shares during the period. Stonepine Capital Management LLC acquired a new position in shares of Pulmonx in the 2nd quarter worth approximately $378,000. Norges Bank acquired a new position in shares of Pulmonx in the 2nd quarter worth approximately $392,000. Finally, XTX Topco Ltd acquired a new position in shares of Pulmonx during the 2nd quarter valued at $149,000. Institutional investors and hedge funds own 91.04% of the company's stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.